Cancer Pain Single Nucleotide Polymorphisms (SNPs)

Cancer pain is common in advanced cancer patients. Opioids are the mainstay of treatment in cancer pain. Responsiveness to and tolerability of opioids is, amongst others, determined by small variations in human DNA. Using blood samples from clinically well-defined cancer pain patients, the investigators are going to analyze single nucleotide polymorphisms (SNPs) in genes that are known to be involved in responsiveness to opioids and sensitivity to pain.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cancer Neoplasms Neurologic Manifestations Pain Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Erasmus MC, Centrumlocatie en Daniel den Hoed

Rotterdam, South Holland, 3000CA, Netherlands

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Cancer pain patients

Exclusion criteria

Patients not able to provide informed consent

Treatment and study plan

Primary outcomes

correlation between pain SNPs and equianalgesic opioid requirement

Time frame: timepoint at blood sample

candidate SNP analysis

Sponsors and collaborators

Lead sponsor

Erasmus Medical Center

Other

Registry information

Official study title

Storage and Analysis of Patient Blood-samples for Cancer Pain Research

Important dates

Study start: 2008
Primary completion: 2012
Study completion: 2012
First posted: Aug 11, 2009
Registry last updated: Dec 24, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed